Navigation Links
By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies
Date:3/31/2009

Washington, DC Researchers at Georgetown University Medical Center (GUMC) have been able to speed recovery and substantially reduce damage resulting from spinal cord injury in preclinical studies.

Their research, published online in Annals of Neurology and led by Kimberly Byrnes, PhD, shows that inflammation following injury causes the neurotoxicity that leads to lasting nerve cell damage, and that an experimental agent is able to block this inflammatory reaction.

"The findings we have made in this study may potentially be applicable to other neurological disorders, including stroke, head injury, Alzheimer's disease and Parkinson's disease," says senior investigator Alan I. Faden, MD, a professor of neuroscience and director of the Laboratory for the Study of Central Nervous System Injury at GUMC.

Faden says that the experimental agent they tested (CHPG), an activator of a type of glutamate receptor, is not ideal for human use because it cannot easily penetrate the blood-brain barrier. But he adds, "now that we know the biological target, a new drug could be designed that is better suited for clinical treatment of these neurodegenerative disorders."

CHPG shuts down activation of key immune cells in the brain known as microglia, which sense pathogens or damage in the spinal cord and brain. They helpfully foster the destruction of microbial invaders and clean up biological detritus that occurs after an injury, but researchers say they have a dark side as well they can worsen the damage by releasing toxic inflammatory factors.

"Under certain conditions, like spinal cord injury and brain trauma, microglia become activated," Faden says. "They release toxic chemicals that can kill healthy adjacent tissue, and this process can continue for months.

"We have found that six months after an injury, the expression of certain inflammatory factors in the spinal cord is 4-5 times normal levels," he says, adding that it has been shown that after human trauma, brain tissue can continue to be lost even more than a year after the injury. "Microglial related toxicity may contribute to this progressive loss," says Faden.

The study is a continuation of a long line of research by this investigative group that aims to stop that persistent damage. The team had previously found that microglial cells express a certain receptor, the group I metabotropic glutamate receptor 5 (mGluR5), on their surface. Further work showed that if these receptors were specifically activated on microglia, these immune cells would not produce the neurotoxins that led to cell death near the site of injury. CHPG serves to selectively activate the receptor, reducing microglial toxicity.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Community & Mission Hospital of Huntington Park Shutting Down Mission Campus, Terminating Workers
2. Pathway links inflammation, angiogenesis and breast cancer
3. Mergent, Inc. Announces Changes to the HealthShares(TM) Composite, Enabling Technologies, Autoimmune-Inflammation, Cancer, Cardiology and Neuroscience Indexes
4. Inflammation, depression and antidepressant response: Common mechanisms
5. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
6. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
7. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
8. MassMutual Agent Honored by Insurance Industry for Extraordinary Service to Client
9. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
10. ABR-Affinity BioReagents Expands 100% Quality Guarantee
11. Inside job: new radioactive agents for colon cancer work inside cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, ... ... a non-profit medical society dedicated to advancing the science and clinical practice ... from its RSSearch Patient Registry, a multi-institutional, observational registry established to standardize ...
(Date:3/28/2017)... ... ... Alert Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced ... Plus. These iSAFE products are the most affordable and most advanced medical alert systems ... direct GPS Location and two-way calling with the push of a button on a ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
(Date:3/28/2017)... , ... March 28, 2017 , ... The Radiology ... FRBMA, has begun to serve as its new executive director. Mr. Still was selected ... Search Committee. , “Bob, as he is known to our members, has been ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical ... begin serving as new board chair for Orange County health care system CalOptima ... remainder of soon-to-be former chair Mark Refowitz’s term, which runs through June 30 ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2016. ... transformational progress for Orexigen, beginning with the re-acquisition of ... early March, the team at Orexigen demonstrated remarkable focus, ... reshaped and strengthened our Company while rewarding us full ...
(Date:3/28/2017)... 2017 The global market for ... the top three companies, namely Shimadzu Corporation, Thermo Fisher ... 49% of the overall market in 2015, observes Transparency ... is intensely competitive and has few players, most of ... factors have restricted the entry of new players in ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 /PRNewswire/ ... Israel . This new business entity, Emosis Ltd, headquartered ... to research and development of novel assays complementing the mother company ... relevant, locally support commercialization and sales development of Emosis kits. ... This strategic move starts ...
Breaking Medicine Technology: